MEDI 491

Drug Profile

MEDI 491

Alternative Names: B19 parvovirus vaccine; Recombinant baculovirus-expressed B19 parvovirus virus-like particle vaccine - MedImmune/NHLBI; Recombinant baculovirus-expressed B19 parvovirus VLP vaccine - MedImmune/NHLBI

Latest Information Update: 21 Jun 2007

Price : $50

At a glance

  • Originator National Heart, Lung and Blood Institute; National Institutes of Health (USA)
  • Developer Chiron Corporation; MedImmune; National Institutes of Health (USA)
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parvovirus infections

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 04 Oct 2004 Discontinued - Phase-I for Parvovirus infections in USA (unspecified route)
  • 20 Mar 2003 A phase I study has been added to the adverse events and Viral Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top